Patients should aim for adequate fluid intake (individualized based on their specific needs and medical conditions) and consume electrolyte-rich foods or beverages, particularly during dose escalation periods
A higher dose of Wegovy (7.2 mg) was approved by the MHRA in January 2026 following the STEP UP trial, which showed: 2 Wegovy 7.2 mg: 20.7% average weight loss Wegovy 2.4 mg: 17.5% average weight loss 50.9% of those on 7.2 mg lost at least 20% of body weight The 7.2 mg dose is not a starting dose
Professional Support for Weight Management Programs Sometimes, your doctor might recommend a more structured weight management program
In June 2021, the FDA approved Wegovy for chronic weight management for adults with obesity (BMI 30kg/m2) or overweight (BMI 27kg/m2) and related comorbidities with at least one weight-related comorbidity, to be administered subcutaneously at 2.4mg once weekly
Recent policy discussions have addressed potential Medicare coverage for obesity medications, but as of late 2025, the prohibition remains in effect
The information can be overwhelming
